ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Type
Public
HQ
Boston, US
Size (employees)
36 (est)+29%
ZIOPHARM Oncology is headquartered in Boston, US

Key People at ZIOPHARM Oncology

Jonathan Lewis

Jonathan Lewis

CEO
Caesar J. Belbel

Caesar J. Belbel

CLO

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston

ZIOPHARM Oncology Data and Metrics

ZIOPHARM Oncology Financial Metrics

ZIOPHARM Oncology's revenue was reported to be $6.9 m in FY, 2016 which is a 58% increase from the previous period.
USD

Revenue (FY, 2016)

6.9 m

Revenue growth (FY, 2015 - FY, 2016), %

58%

Net income (FY, 2016)

(165.3 m)

EBIT (FY, 2016)

(165.3 m)

Market capitalization (26-Jun-2017)

823.4 m

Closing share price (26-Jun-2017)

6.2

Cash (31-Dec-2016)

81.1 m
ZIOPHARM Oncology's current market capitalization is $823.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

800 k1.4 m4.3 m6.9 m

Revenue growth, %

72%216%58%

Operating expense total

359.2 m44.9 m124.4 m172.2 m

EBIT

(356.9 m)(43.5 m)(120.1 m)(165.3 m)

EBIT margin, %

(44614%)(3168%)(2772%)(2409%)

Net Income

(340.8 m)(31.8 m)(120.1 m)(165.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

68.2 m42.8 m140.7 m81.1 m

Inventories

1.9 m1.1 m11.4 m23.8 m

Current Assets

70.3 m44.1 m152.5 m104.9 m

PP&E

801 k531 k581 k843 k

Total Assets

71.8 m45.2 m153.7 m106.3 m

Accounts Payable

422 k2 m2 m156 k

Current Liabilities

7.8 m10.8 m18.1 m15.8 m

Retained Earnings

(372.6 m)(492.7 m)(658 m)

Total Equity

49.4 m33.8 m87.4 m(77.3 m)

Financial Leverage

1.5 x1.3 x1.8 x-1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(57.1 m)(31.8 m)(120.1 m)(165.3 m)

Depreciation and Amortization

738 k462 k357 k290 k

Inventories

5 m809 k(10 m)(12 m)

Accounts Payable

(1.1 m)1.6 m4 k(1.9 m)

Cash From Operating Activities

(59.5 m)(36.7 m)(10 k)(58.3 m)

Purchases of PP&E

(132 k)(193 k)(412 k)(551 k)

Cash From Investing Activities

(131 k)(193 k)(412 k)(551 k)

Cash From Financing Activities

54.5 m11.4 m98.3 m(788 k)
Y, 2016

Financial Leverage

-1.4 x

ZIOPHARM Oncology Market Value History

ZIOPHARM Oncology News and Updates

ZIOPHARM Oncology Company Life and Culture

You may also be interested in